References in periodicals archive ?
The Phase 4 Trial Evaluating XEOMIN (incobotulinumtoxinA) for cervical dystonia or blepharospasm in the United States (XCiDaBLE) is a prospective, observational study.
Myobloc(R) (Botulinum Toxin Type B) Injectable Solution was the first FDA-approved neurotoxin indicated for the neck pain and abnormal head position associated with cervical dystonia.
Ipsen to launch DYSPORT(TM) (abobotulinumtoxinA) for cervical dystonia during the second half of 2009
Merz is committed to supporting patients and physicians in the cervical dystonia and blepharospasm community.
In January 2001, the European Commission granted Marketing Authorization valid throughout the European Union (EU) for NeuroBloc, also known as Myobloc(R) (Botulinum Toxin Type B) Injectable Solution in the United States, for the treatment of cervical dystonia.
Dysport([R]) has been approved as a treatment for cervical dystonia, an orphan disease in the United States.
In December 2006, Eisai filed the new drug application for this product in Japan for the treatment of Cervical Dystonia.
Dysphagia (difficulty swallowing) is a commonly reported adverse event following treatment of cervical dystonia patients with all botulinum toxins.
focal dystonia (which includes cervical dystonia and blepharospasm) is estimated to affect 295 per million people in the U.
Myobloc(R) (Botulinum Toxin Type B) Injectable Solution was the first drug approved in the US to reduce the severity of abnormal head position and the neck pain associated with cervical dystonia.
Food and Drug Administration (FDA) provided notification that the Prescription Drug User Fee Act (PDUFA) action date for Dysport([R]) (botulinum toxin of type A) Biologics License Application (BLA) for the treatment of patients with cervical dystonia has been extended to no later than 28 December 2008.
Despite being diagnosed with the movement disorder Cervical Dystonia (CD) at the age of 32, Brinkley was crowned Mrs.